Eloise C. Salmon

Eloise C. Salmon

Pediatric Nephrology | Pediatrics

1540 E Hospital Dr
Floor 8 Reception B
Ann Arbor, MI 48109

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Patient-Focused Drug Development in Kidney Disease: Including Fit-for-Purpose Outcomes in Trials.

Patient-Focused Drug Development in Kidney Disease: Including Fit-for-Purpose Outcomes in Trials.

Journal: Journal of the American Society of Nephrology : JASN

Published: January 21, 2026

How Much Change Is Meaningful in Global Impression Anchors? Evidence From 5 Rare Diseases.

How Much Change Is Meaningful in Global Impression Anchors? Evidence From 5 Rare Diseases.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: November 26, 2025

Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome.

Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome.

Journal: medRxiv : the preprint server for health sciences

Published: September 19, 2025

Polygenic risk scores and HLA class II variants are biomarkers of corticosteroid response in childhood nephrotic syndrome.

Polygenic risk scores and HLA class II variants are biomarkers of corticosteroid response in childhood nephrotic syndrome.

Journal: Kidney international

Published: August 06, 2025

Clinical Outcome Assessment Endpoints in Nephrotic Syndrome Drug Development: Research Partner Feedback on Patient-Centered Trial Design.

Clinical Outcome Assessment Endpoints in Nephrotic Syndrome Drug Development: Research Partner Feedback on Patient-Centered Trial Design.

Journal: Glomerular diseases

Published: June 13, 2025

Prediabetes in Children and Adults with Glomerular Disease.

Prediabetes in Children and Adults with Glomerular Disease.

Journal: Glomerular diseases

Published: May 30, 2025

Emerging pharmacotherapies for the treatment of childhood nephrotic syndrome.

Emerging pharmacotherapies for the treatment of childhood nephrotic syndrome.

Journal: Expert opinion on pharmacotherapy

Published: April 15, 2025

RESOLVE: Recurrence Posttransplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease.

RESOLVE: Recurrence Posttransplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease.

Journal: Glomerular diseases

Published: September 06, 2024

Comparing adolescent glomerular disease clinical outcomes to the clinical outcomes in childhood, young adult, and adult-onset glomerular disease in the CureGN database.

Comparing adolescent glomerular disease clinical outcomes to the clinical outcomes in childhood, young adult, and adult-onset glomerular disease in the CureGN database.

Journal: Pediatric nephrology (Berlin, Germany)

Published: June 26, 2024

Preparation and Rationale for a Patient-Centered Clinical Outcome Assessment Set of Fluid Overload for Drug Development in Nephrotic Syndrome.

Preparation and Rationale for a Patient-Centered Clinical Outcome Assessment Set of Fluid Overload for Drug Development in Nephrotic Syndrome.

Journal: Glomerular diseases

Published: October 23, 2023

FSGS Recurrence Collaboration: Report of a Symposium.

FSGS Recurrence Collaboration: Report of a Symposium.

Journal: Glomerular diseases

Published: July 19, 2023

The Health Economic Impact of Nephrotic Syndrome in the United States.

The Health Economic Impact of Nephrotic Syndrome in the United States.

Journal: Kidney360

Published: September 28, 2021

Showing 1-12 of 14

Last Updated: 09/26/2026